Bookmark and Share
KUC109881N (CID 53308671) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(9)
 
 
Inactive(16)
 
 
Top Targets:
PTZ00371(5)
 
 
 
M1 APN 1(1)
 
 
Peptidase M17(1)
 
 
BioAssay Types:
Confirmatory(18)
 
 
 
BioActivity Types:
IC50(13)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 14    Data Row: 25   Total Pages: 1   
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID124767905]
IC50 4.5Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (M18AAP): radiolabel-based cell-based dose response assay to identify compounds that inhibit P. falciparum growth in RBCs, Set 2. [AID743024, Type: confirmatory]
View
2
[SID135378317]
Avg CC50 9.77Vero Cytoxicity Assay: A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP) (3) [AID624205, Type: confirmatory]
View
3
[SID135378308]
Avg CC50 12.93Vero Cytoxicity Assay: A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP) (3) [AID624205, Type: confirmatory]
View
4
[SID124767905]
Average CC50 15.9Vero Cytoxicity Assay: A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP) [AID588714, Type: confirmatory]
View
5
[SID124767905]
Average CC50 27.84Vero Cytoxicity Assay: A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP) (2) [AID602225, Type: confirmatory]
View
6
[SID124767905]
Avg CC50 40.78Vero Cytoxicity Assay: A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Plasmodium falciparum M17 Leucine Aminopeptidase (PFM17LAP) (3) [AID602317, Type: confirmatory]
View
7
[SID124767905]
Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (M18AAP): radiolabel-based cell-based assay to identify compounds that inhibit P. falciparum growth in RBCs, Set2 [AID720736_1, Type: other]M18 aspartyl aminopeptidase [Plasmodium falciparum 3D7] [gi:124507185]
View
8
[SID124767905]
Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (M18AAP): radiolabel-based cell-based assay to identify compounds that inhibit P. falciparum growth in RBCs, Set2 [AID720736_2, Type: other]M18 aspartyl aminopeptidase [Plasmodium falciparum 3D7] [gi:124507185]
View
9
[SID124767905]
Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (M18AAP): radiolabel-based cell-based assay to identify compounds that inhibit P. falciparum growth in RBCs, Set2 [AID720736, Type: other]
View
10
[SID124767905]
Average M17 IC50 Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M17 Leucine Aminopeptidase (PFM17LAP) [AID588679, Type: confirmatory]M17 leucyl aminopeptidase [Plasmodium falciparum 3D7] [gi:23497510]
View
11
[SID124767905]
Average IC50 QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP) [AID588678, Type: confirmatory]M18 aspartyl aminopeptidase [Plasmodium falciparum 3D7] [gi:23505220]
View
12
[SID124767905]
Average PFM1AAP IC50 Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M1AAP (PFM1AAP) [AID588680, Type: confirmatory]m1-family aminopeptidase [Plasmodium falciparum 3D7] [gi:23615263]
View
13
[SID135378308]
Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (M18AAP): radiolabel-based cell-based assay to identify compounds that inhibit P. falciparum growth in RBCs, Set2 [AID720736, Type: other]
View
14
[SID135378317]
Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (M18AAP): radiolabel-based cell-based assay to identify compounds that inhibit P. falciparum growth in RBCs, Set2 [AID720736, Type: other]
View
15
[SID135378308]
Average PFM18AAP IC50 QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP) (2) [AID624177, Type: confirmatory]
View
16
[SID135378308]
Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (M18AAP): radiolabel-based cell-based assay to identify compounds that inhibit P. falciparum growth in RBCs, Set2 [AID720736_1, Type: other]M18 aspartyl aminopeptidase [Plasmodium falciparum 3D7] [gi:124507185]
View
17
[SID135378317]
Late stage assay provider results from the probe development effort to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (M18AAP): radiolabel-based cell-based assay to identify compounds that inhibit P. falciparum growth in RBCs, Set2 [AID720736_1, Type: other]M18 aspartyl aminopeptidase [Plasmodium falciparum 3D7] [gi:124507185]
View
18
[SID124767905]
Average hM18AAP IC50 Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the human M18 Aspartyl Aminopeptidase (hM18AAP) [AID588696, Type: confirmatory]Chain A, Crystal Structure Of Human Aspartyl Aminopeptidase (Dnpep), In Complex With Aspartic Acid Hydroxamate [gi:291191219]
View
19
[SID135378308]
Average Hum18AAP IC50 Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the human M18 Aspartyl Aminopeptidase (hM18AAP) (3) [AID624174, Type: confirmatory]
View
20
[SID135378308]
Average PFM17LAP IC50 Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M17 Leucine Aminopeptidase (PFM17LAP) (3) [AID624175, Type: confirmatory]
View
21
[SID135378308]
Average PFM1AAP IC50 Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M1AAP (PFM1AAP) (3) [AID624176, Type: confirmatory]
View
22
[SID135378317]
Average Hum18AAP IC50 Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the human M18 Aspartyl Aminopeptidase (hM18AAP) (3) [AID624174, Type: confirmatory]
View
23
[SID135378317]
Average PFM17LAP IC50 Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M17 Leucine Aminopeptidase (PFM17LAP) (3) [AID624175, Type: confirmatory]
View
24
[SID135378317]
Average PFM1AAP IC50 Counterscreen for inhibitors of PFM18AAP: QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M1AAP (PFM1AAP) (3) [AID624176, Type: confirmatory]
View
25
[SID135378317]
Average PFM18AAP IC50 QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP) (2) [AID624177, Type: confirmatory]
View